The study of 4 mg of ITI-3000 in polyomavirus-positive Merkel Cell Carcinoma
The company Immunomic Therapeutics, Inc is commencing recruitment for the clinical trial to evaluate the safety, tolerability and immunogenicity of 4 mg Of ITI-3000 in patients with polyomavirus-positive Merkel Cell Carcinoma (MCC).
A new clinical trial is recruiting patients in the following locations: United States. The trial officially began on the June 2022 and is planned to complete on June 2023.
This Phase I clinical trial will evaluate the safety, tolerability, and immunogenicity of 4 mg doses of ITI-3000 in participants with polyomavirus-positive Merkel cell carcinoma (MCC).
ncers are eligible if the treatment was completed more than 3 years prior to initiating current study treatment, and there is no evidence of recurrent disease. - Participant has a significant medical illness or abnormal laboratory finding that, in the Investigator's opinion, would increase the risk of participating in this study. - Participant with otherwise unexplained >10% weight loss in the last 30 days prior to the screening. - Participant has evidence of serious active infection (i.e., infection requiring treatment with intravenous antibiotics).
The link to the complete study profile: https://ichgcp.net/clinical-trials-registry/NCT05422781 or https://clinicaltrials.gov/ct2/show/NCT05422781.
